Companies 0 See All
Hedge Funds 0 See All
Insiders 0 See All
Institutional Investors 0 See All
Click here to see all results for
Hedge Funds-News

13G Filing: Scopia Capital Raises Stake in Insys Therapeutics, Inc. (INSY)

Published on March 11, 2016 at 10:13 am by Meena Krishnamsetty in Hedge Funds, News

Matt Sirovich and Jeremy Mindich‘s Scopia Capital has disclosed a position in Insys Therapeutics Inc (NASDAQ:INSY) via a 13G filing with the US Securities and Exchange Commission. According to the filing, Scopia owns some 7.43 million shares of Insys, which represent 10.40% of the company’s outstanding common stock. This compares with the 5.82 million shares of Insys that Scopia reported in its latest 13F filing, for the end of the fourth quarter of 2015. It’s also important to mention that Scopia boosted its stake by 238% during the fourth quarter.

Insys Therapeutics Inc (NASDAQ:INSY) shareholders have witnessed an increase in hedge fund sentiment lately. At the end of the fourth quarter, a total of 20 of the hedge funds tracked by Insider Monkey were bullish on this stock, up by 33% from the previous quarter. With the smart money’s sentiment swirling, there exists a few key hedge fund managers who were increasing their holdings meaningfully (or already accumulated large positions).

According to Insider Monkey’s hedge fund database, Scopia Capital has the number one position in Insys Therapeutics Inc (NASDAQ:INSY), followed by OrbiMed Advisors, managed by Samuel Isaly, which holds a $125 million position as of December 31; the fund has 1.1% of its 13F portfolio invested in the stock. Some other members of the smart money with similar optimism contain Mitchell Blutt’s Consonance Capital Management, Solomon Kumin’s Folger Hill Asset Management and Joel Greenblatt’s Gotham Asset Management.

Consequently, some big names were leading the bulls’ herd. Folger Hill Asset Management, managed by Solomon Kumin, established the biggest position in Insys Therapeutics Inc (NASDAQ:INSY). Folger Hill Asset Management had $28.6 million invested in the company at the end of the quarter. Joel Greenblatt’s Gotham Asset Management also initiated a $23.8 million position during the quarter. The other funds with brand new INSY positions are Eric Chen’s Antipodean Advisors, Christopher R. Hansen’s Valiant Capital, and Phill Gross and Robert Atchinson’s Adage Capital Management.

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Scopia Capital Management 0 7,434,936 0 7,434,936 7,434,936 10.40%
Scopia Management, Inc 0 7,434,936 0 7,434,936 7,434,936 10.40%
Matthew Sirovich 0 7,434,936 0 7,434,936 7,434,936 10.40%
Jeremy Mindich 0 7,434,936 0 7,434,936 7,434,936 10.40%

Follow Matt Sirovich And Jeremy Mindich's Scopia Capital

Page 1 of 12 SEC Filing

UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No.
1)*
Insys Therapeutics, Inc.
(Name of Issuer)
Common Stock, $0.01 par value
(Title of Class of Securities)
45824V209
(CUSIP Number)
February 29,
2016
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
[X]      Rule 13d-1(b)
[_]      Rule 13d-1(c)
[_]      Rule 13d-1(d)
_________
(1) The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed’ for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Follow Insys Therapeutics Inc. (NASDAQ:INSY)

Page 2 of 12 SEC Filing

CUSIP No.
45824V209
1.
NAME OF REPORTING PERSONS:  Scopia Capital Management LP
2.
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
(a)  [_]
(b)  [X]
3.
SEC USE ONLY
4.
CITIZENSHIP OR PLACE OF ORGANIZATION
United States
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
5.
SOLE VOTING POWER
0
6.
SHARED VOTING POWER
7,434,936
7.
SOLE DISPOSITIVE POWER
0
8.
SHARED DISPOSITIVE POWER
7,434,936
9.
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
7,434,936
10.
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
[_]
11.
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
10.40%
12.
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
PN, IA

Follow Insys Therapeutics Inc. (NASDAQ:INSY)

Page 3 of 12 SEC Filing

CUSIP No.
45824V209
1.
NAME OF REPORTING PERSONS:  Scopia Management, Inc.
2.
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
(a)  [_]
(b)  [X]
3.
SEC USE ONLY
4.
CITIZENSHIP OR PLACE OF ORGANIZATION
United States
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
5.
SOLE VOTING POWER
0
6.
SHARED VOTING POWER
7,434,936
7.
SOLE DISPOSITIVE POWER
0
8.
SHARED DISPOSITIVE POWER
7,434,936
9.
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
7,434,936
10.
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
[_]
11.
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
10.40%
12.
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
CO

Follow Insys Therapeutics Inc. (NASDAQ:INSY)

Page 4 of 12 SEC Filing

CUSIP No.
45824V209
1.
NAME OF REPORTING PERSONS:  Matthew Sirovich
2.
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
(a)  [_]
(b)  [X]
3.
SEC USE ONLY
4.
CITIZENSHIP OR PLACE OF ORGANIZATION
United States
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
5.
SOLE VOTING POWER
0
6.
SHARED VOTING POWER
7,434,936
7.
SOLE DISPOSITIVE POWER
0
8.
SHARED DISPOSITIVE POWER
7,434,936
9.
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
7,434,936
10.
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
[_]
11.
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
10.40%
12.
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
IN

Follow Insys Therapeutics Inc. (NASDAQ:INSY)

Page 5 of 12 SEC Filing

CUSIP No.
45824V209
1.
NAME OF REPORTING PERSONS:  Jeremy Mindich
2.
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
(a)  [_]
(b)  [X]
3.
SEC USE ONLY
4.
CITIZENSHIP OR PLACE OF ORGANIZATION
United States
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
5.
SOLE VOTING POWER
0
6.
SHARED VOTING POWER
7,434,936
7.
SOLE DISPOSITIVE POWER
0
8.
SHARED DISPOSITIVE POWER
7,434,936
9.
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
7,434,936
10.
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
[_]
11.
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
10.40%
12.
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
IN

Follow Insys Therapeutics Inc. (NASDAQ:INSY)

Page 6 of 12 SEC Filing

CUSIP No.
45824V209
Item 1.
(a).
Name of Issuer:
Insys Therapeutics, Inc.
(b).
Address of Issuer’s Principal Executive Offices:
1333 S. Spectrum Blvd, Suite 100
Chandler, Arizona 85286
Item 2.
(a).
Name of Person Filing:
Scopia Capital Management LP
Scopia Management, Inc.
Matthew Sirovich
Jeremy Mindich
(b).
Address or Principal Business Office or, if None, Residence:
Scopia Capital Management LP
152 West 57th Street, 33rd Floor
New York, NY 10019
Scopia Management, Inc.
Matthew Sirovich
Jeremy Mindich
c/o Scopia Capital Management LP
152 West 57th Street, 33rd Floor
New York, NY 10019
(c).
Citizenship:
Scopia Capital Management LP – Delaware limited partnership
Scopia Management, Inc. – New York corporation
Matthew Sirovich – United States citizen
Jeremy Mindich – United States citizen
(d).
Title of Class of Securities:
Common Stock, $0.01 par value
(e).
CUSIP Number:
45824V209
Item 3.
If this statement is filed pursuant to §§.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a:
(a)
[_]
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
(b)
[_]
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
(c)
[_]
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
(d)
[_]
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
(e)
[X]
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
[_]
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
[X]
A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
(h)
[_]
A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
(i)
[_]
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
[_]
A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
(k)
[_]
Group, in accordance with §240.13d-1(b)(1)(ii)(K).  If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

Follow Insys Therapeutics Inc. (NASDAQ:INSY)

Page 7 of 12 SEC Filing

CUSIP No.
45824V209
Item 4.
Ownership.
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
Scopia Capital Management LP
(a)
Amount beneficially owned:
7,434,936
(b)
Percent of class:
10.40%
(c)
Number of shares as to which the person has:
(i)
Sole power to vote or to direct the vote
0
,
(ii)
Shared power to vote or to direct the vote
7,434,936
,
(iii)
Sole power to dispose or to direct the disposition of
0
,
(iv)
Shared power to dispose or to direct the disposition of
7,434,936
.
Scopia Management, Inc.
(a)
Amount beneficially owned:
7,434,936
(b)
Percent of class:
10.40%
(c)
Number of shares as to which the person has:
(i)
Sole power to vote or to direct the vote
0
,
(ii)
Shared power to vote or to direct the vote
7,434,936
,
(iii)
Sole power to dispose or to direct the disposition of
0
,
(iv)
Shared power to dispose or to direct the disposition of
7,434,936
.

Follow Insys Therapeutics Inc. (NASDAQ:INSY)

Page 8 of 12 SEC Filing

Matthew Sirovich
(a)
Amount beneficially owned:
7,434,936
(b)
Percent of class:
10.40%
(c)
Number of shares as to which the person has:
(i)
Sole power to vote or to direct the vote
0
,
(ii)
Shared power to vote or to direct the vote
7,434,936
,
(iii)
Sole power to dispose or to direct the disposition of
0
,
(iv)
Shared power to dispose or to direct the disposition of
7,434,936
.
Jeremy Mindich
(a)
Amount beneficially owned:
7,434,936
(b)
Percent of class:
10.40%
(c)
Number of shares as to which the person has:
(i)
Sole power to vote or to direct the vote
  0
,
(ii)
Shared power to vote or to direct the vote
7,434,936
.
(iii)
Sole power to dispose or to direct the disposition of
  0
,
(iv)
Shared power to dispose or to direct the disposition of
7,434,936
.

Follow Insys Therapeutics Inc. (NASDAQ:INSY)

Page 9 of 12 SEC Filing

Item 5.
Ownership of Five Percent or Less of a Class.
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  [  ].
N/A
Item 6.
Ownership of More Than Five Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
All securities reported in this Schedule 13G are owned by advisory clients of Scopia Capital Management LP.  None of such advisory clients individually own more than 5% of the Issuer’s outstanding shares.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company or Control person has filed this schedule, pursuant to Rule 13d-1(b) (1) (ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary.
Please see Exhibit B attached hereto.
Item 8.
Identification and Classification of Members of the Group.
If a group has filed this schedule pursuant to ss.240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §§ 240.13d-1(c) or §§ 240.13d-1(d), attach an exhibit stating the identity of each member of the group.
N/A
Item 9.
Notice of Dissolution of Group.
Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.
N/A
Item 10.
Certification.
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Follow Insys Therapeutics Inc. (NASDAQ:INSY)

Page 10 of 12 SEC Filing

SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
March 10, 2016
(Date)
SCOPIA CAPITAL MANAGEMENT LP
By: /s/ Aaron Morse
Name:  Aaron Morse
Title:  COO
SCOPIA MANAGEMENT, INC.
By: /s/ Aaron Morse
Name:  Aaron Morse
Title:  Vice President
By: /s/ Matthew Sirovich
Name:  Matthew Sirovich
By: /s/ Jeremy Mindich
Name:  Jeremy Mindich
Note.  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties for whom copies are to be sent.
Attention.  Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

Follow Insys Therapeutics Inc. (NASDAQ:INSY)

Page 11 of 12 SEC Filing

Exhibit A
AGREEMENT
The
undersigned agree that this Schedule 13G dated March 10, 2016 relating to the Common Stock, $0.01 par value of Insys
Therapeutics, Inc. shall be filed on behalf of the undersigned.
SCOPIA CAPITAL MANAGEMENT LP
By: /s/ Aaron Morse
Name:  Aaron Morse
Title:  COO
SCOPIA MANAGEMENT, INC.
By: /s/ Aaron Morse
Name:  Aaron Morse
Title:  Vice President
By: /s/ Matthew Sirovich
Name:  Matthew Sirovich
By: /s/ Jeremy Mindich
Name:  Jeremy Mindich

Follow Insys Therapeutics Inc. (NASDAQ:INSY)

Page 12 of 12 SEC Filing

Exhibit B
Matthew Sirovich and Jeremy Mindich may be considered control persons of Scopia Capital GP LLC.

Follow Insys Therapeutics Inc. (NASDAQ:INSY)

Show more...Show less

Related Insider Monkey Articles
Scopia Capital Discards Stake In RetailMeNot Inc. (SALE); Two Other Bullish...13D Filing: Scopia Capital Reveals Big Stake in Conmed Corp (CNMD)
Starboard Value Cuts Stake in RealD (RLD), Stadium Capital Buys More of This...13G Filing: Scopia Capital and Neuroderm Ltd (NDRM)
Three Hedge Fund Moves Ahead Of HolidaysCONMED Corp (CNMD): Scopia Capital Isn't Done Buying Shares